Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Abstract Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive activation of the KRAS protein, which acts as...
Guardado en:
Autores principales: | Gongmin Zhu, Lijiao Pei, Hongwei Xia, Qiulin Tang, Feng Bi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a5cb9fa2bdcc4009ba782630d37a3d2e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
por: Hidayati Husainy Hasbullah, et al.
Publicado: (2021) -
KRAS and NRAS genes mutations as biomarkers in the therapy of colorectal cancer and the basic methods of their detection
por: Olga I. Brovkina, et al.
Publicado: (2021) -
Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
por: M. I. Sekacheva, et al.
Publicado: (2020) -
Oncogenic KRAS: Signaling and Drug Resistance
por: Hyeon Jin Kim, et al.
Publicado: (2021) -
Recent insights into nanotechnology development for detection and treatment of colorectal cancer
por: Viswanath B, et al.
Publicado: (2016)